Track topics on Twitter Track topics that are important to you
Do idiopathic pulmonary fibrosis patients benefit from continued treatment with pirfenidone -- particularly those who experienced meaningful disease progression during treatment? Thorax
Researchers found pirfenidone had an acceptable tolerability profile for the treatment of patients with systemic sclerosis-associated interstitial lung disease and suggested tolerability may improve w...
NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Kadmon Corporation, LLC today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company's rho-associated coiled-co...
DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercializatio...
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen plc (LON:SNG). Its shares are trading at a fraction of what would be c...
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to ev...
Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most commonly encountered in an older ...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of s...
Desmoplasia in human pancreatic cancer (PC) promotes cancer progression and hinders effective drug delivery. The objectives of this study were to characterize a homologous orthotopic model of PC in Sy...